Current Report Filing (8-k)
April 20 2021 - 4:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (date of earliest event reported): April 19, 2021
QSAM
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-55148
|
|
20-1602779
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
Number)
|
9442
Capital of Texas Hwy N, Plaza 1, Suite 500
Austin,
Texas
|
|
78759
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
|
|
(512)
343-4558
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Items
On
April 19, 2021, the Company issued a letter to shareholders / press release relating to accomplishments in 2020, future milestones,
and explanations of certain items in the Company’s Form 10-K filed on April 15, 2021. A copy of the press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 is being furnished and such information shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ( the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in
any filing under the Securities Act of 1933, as amended or the Exchange Act, except as may be expressly set forth by specific
reference in such a filing/
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
QSAM
Biosciences, Inc.
|
|
|
|
By:
|
/s/
Christopher Nelson
|
|
|
Christopher
Nelson
|
|
|
General
Counsel
|
|
|
|
|
|
Date:
April 20, 2021
|
Common Stock (QB) (USOTC:QSAM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Common Stock (QB) (USOTC:QSAM)
Historical Stock Chart
From Sep 2023 to Sep 2024